ATRA
Atara Biotherapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$8.29-1.19%
Price as of Jul 20, 2026
ATRA profitability
Atara Biotherapeutics, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 96.1%
- EBITDA margin
- -23.7%
- EBIT margin
- -27.3%
- Net margin
- -40.9%
- Free cash flow margin
- -111.8%
Returns
- Return on equity
- 25.4%
- Return on assets
- -47.3%
- Return on invested capital
- 23.2%
- Asset turnover
- 1.15x
Cash efficiency
- Cash from operations
- -$25.9M
- Cash per share
- $0.93
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.